Clinical predictors of Alzheimer's disease progression

Nozomi Hishikawa, Yusuke Fukui, Mami Takemoto, Kota Sato, Jingwei Shang, Toru Yamashita, Yasuyuki Ohta, Koji Abe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: Rates of disease progression differ among patients with Alzheimer's disease (AD), but prognostic predictions remain a challenge. We carried out a clinic-based retrospective study to investigate the clinical factors for AD progression. Methods: The 748 AD patients, who attended our hospital for >1 year and were given the Mini-Mental State Examination (MMSE) at least three times, were divided into three groups according to the annual change rate of MMSE score (G): Aggravater group (G < −2), Stabler group (−2 ≤ G ≤ 2) and Improver group (2 < G). We compared the three groups on cognitive, affective and activities of daily living functions, response to medication, clinical fluctuations, serum levels of metabolic factors, and neuroimaging data. Results: We found no significant differences in age, sex, educational attainment or body mass index across the groups. The Aggravater group showed better baseline MMSE (P < 0.01) and Abe's behavioral and psychological symptoms of dementia (P < 0.01) scores than the Improver group, but its MMSE improvement after drug treatment was the worst among the three groups (P < 0.01 vs Stabler/Improver). Fluctuations in MMSE (P < 0.01), apathy scale (P < 0.05) and activities of daily living (P < 0.01) scores were smaller in the Improver group than in the Aggravater or Stabler groups. Serum docosahexaenoic acid levels tended to be lower (trend P < 0.05) and voxel-based specific regional analysis system for Alzheimer's disease Z-scores tended to be higher (trend P < 0.05) in the Improver group than in the Stabler or Aggravater groups. Conclusions: Initial responses to medication, fluctuations in cognitive, affective and activities of daily living functions, serum docosahexaenoic acid levels, and medial temporal atrophy are clinical factors related to AD prognosis. Geriatr Gerontol Int 2018; 18: 929–936.

Original languageEnglish
Pages (from-to)929-936
Number of pages8
JournalGeriatrics and Gerontology International
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

dementia
Disease Progression
Alzheimer Disease
Activities of Daily Living
Docosahexaenoic Acids
Group
Serum
Apathy
Behavioral Symptoms
examination
fluctuation
Neuroimaging
Atrophy
Dementia
Body Mass Index
Retrospective Studies
Psychology
medication
regional analysis
apathy

Keywords

  • activities of daily living
  • apathy
  • cognitive function
  • fluctuation
  • response to medication

ASJC Scopus subject areas

  • Health(social science)
  • Gerontology
  • Geriatrics and Gerontology

Cite this

Clinical predictors of Alzheimer's disease progression. / Hishikawa, Nozomi; Fukui, Yusuke; Takemoto, Mami; Sato, Kota; Shang, Jingwei; Yamashita, Toru; Ohta, Yasuyuki; Abe, Koji.

In: Geriatrics and Gerontology International, Vol. 18, No. 6, 01.06.2018, p. 929-936.

Research output: Contribution to journalArticle

@article{3a090feabf4344c4a278d5adc87d2e43,
title = "Clinical predictors of Alzheimer's disease progression",
abstract = "Aim: Rates of disease progression differ among patients with Alzheimer's disease (AD), but prognostic predictions remain a challenge. We carried out a clinic-based retrospective study to investigate the clinical factors for AD progression. Methods: The 748 AD patients, who attended our hospital for >1 year and were given the Mini-Mental State Examination (MMSE) at least three times, were divided into three groups according to the annual change rate of MMSE score (G): Aggravater group (G < −2), Stabler group (−2 ≤ G ≤ 2) and Improver group (2 < G). We compared the three groups on cognitive, affective and activities of daily living functions, response to medication, clinical fluctuations, serum levels of metabolic factors, and neuroimaging data. Results: We found no significant differences in age, sex, educational attainment or body mass index across the groups. The Aggravater group showed better baseline MMSE (P < 0.01) and Abe's behavioral and psychological symptoms of dementia (P < 0.01) scores than the Improver group, but its MMSE improvement after drug treatment was the worst among the three groups (P < 0.01 vs Stabler/Improver). Fluctuations in MMSE (P < 0.01), apathy scale (P < 0.05) and activities of daily living (P < 0.01) scores were smaller in the Improver group than in the Aggravater or Stabler groups. Serum docosahexaenoic acid levels tended to be lower (trend P < 0.05) and voxel-based specific regional analysis system for Alzheimer's disease Z-scores tended to be higher (trend P < 0.05) in the Improver group than in the Stabler or Aggravater groups. Conclusions: Initial responses to medication, fluctuations in cognitive, affective and activities of daily living functions, serum docosahexaenoic acid levels, and medial temporal atrophy are clinical factors related to AD prognosis. Geriatr Gerontol Int 2018; 18: 929–936.",
keywords = "activities of daily living, apathy, cognitive function, fluctuation, response to medication",
author = "Nozomi Hishikawa and Yusuke Fukui and Mami Takemoto and Kota Sato and Jingwei Shang and Toru Yamashita and Yasuyuki Ohta and Koji Abe",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/ggi.13286",
language = "English",
volume = "18",
pages = "929--936",
journal = "Geriatrics and Gerontology International",
issn = "1447-0594",
publisher = "Japan Geriatrics Society",
number = "6",

}

TY - JOUR

T1 - Clinical predictors of Alzheimer's disease progression

AU - Hishikawa, Nozomi

AU - Fukui, Yusuke

AU - Takemoto, Mami

AU - Sato, Kota

AU - Shang, Jingwei

AU - Yamashita, Toru

AU - Ohta, Yasuyuki

AU - Abe, Koji

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Aim: Rates of disease progression differ among patients with Alzheimer's disease (AD), but prognostic predictions remain a challenge. We carried out a clinic-based retrospective study to investigate the clinical factors for AD progression. Methods: The 748 AD patients, who attended our hospital for >1 year and were given the Mini-Mental State Examination (MMSE) at least three times, were divided into three groups according to the annual change rate of MMSE score (G): Aggravater group (G < −2), Stabler group (−2 ≤ G ≤ 2) and Improver group (2 < G). We compared the three groups on cognitive, affective and activities of daily living functions, response to medication, clinical fluctuations, serum levels of metabolic factors, and neuroimaging data. Results: We found no significant differences in age, sex, educational attainment or body mass index across the groups. The Aggravater group showed better baseline MMSE (P < 0.01) and Abe's behavioral and psychological symptoms of dementia (P < 0.01) scores than the Improver group, but its MMSE improvement after drug treatment was the worst among the three groups (P < 0.01 vs Stabler/Improver). Fluctuations in MMSE (P < 0.01), apathy scale (P < 0.05) and activities of daily living (P < 0.01) scores were smaller in the Improver group than in the Aggravater or Stabler groups. Serum docosahexaenoic acid levels tended to be lower (trend P < 0.05) and voxel-based specific regional analysis system for Alzheimer's disease Z-scores tended to be higher (trend P < 0.05) in the Improver group than in the Stabler or Aggravater groups. Conclusions: Initial responses to medication, fluctuations in cognitive, affective and activities of daily living functions, serum docosahexaenoic acid levels, and medial temporal atrophy are clinical factors related to AD prognosis. Geriatr Gerontol Int 2018; 18: 929–936.

AB - Aim: Rates of disease progression differ among patients with Alzheimer's disease (AD), but prognostic predictions remain a challenge. We carried out a clinic-based retrospective study to investigate the clinical factors for AD progression. Methods: The 748 AD patients, who attended our hospital for >1 year and were given the Mini-Mental State Examination (MMSE) at least three times, were divided into three groups according to the annual change rate of MMSE score (G): Aggravater group (G < −2), Stabler group (−2 ≤ G ≤ 2) and Improver group (2 < G). We compared the three groups on cognitive, affective and activities of daily living functions, response to medication, clinical fluctuations, serum levels of metabolic factors, and neuroimaging data. Results: We found no significant differences in age, sex, educational attainment or body mass index across the groups. The Aggravater group showed better baseline MMSE (P < 0.01) and Abe's behavioral and psychological symptoms of dementia (P < 0.01) scores than the Improver group, but its MMSE improvement after drug treatment was the worst among the three groups (P < 0.01 vs Stabler/Improver). Fluctuations in MMSE (P < 0.01), apathy scale (P < 0.05) and activities of daily living (P < 0.01) scores were smaller in the Improver group than in the Aggravater or Stabler groups. Serum docosahexaenoic acid levels tended to be lower (trend P < 0.05) and voxel-based specific regional analysis system for Alzheimer's disease Z-scores tended to be higher (trend P < 0.05) in the Improver group than in the Stabler or Aggravater groups. Conclusions: Initial responses to medication, fluctuations in cognitive, affective and activities of daily living functions, serum docosahexaenoic acid levels, and medial temporal atrophy are clinical factors related to AD prognosis. Geriatr Gerontol Int 2018; 18: 929–936.

KW - activities of daily living

KW - apathy

KW - cognitive function

KW - fluctuation

KW - response to medication

UR - http://www.scopus.com/inward/record.url?scp=85044312539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044312539&partnerID=8YFLogxK

U2 - 10.1111/ggi.13286

DO - 10.1111/ggi.13286

M3 - Article

C2 - 29569404

AN - SCOPUS:85044312539

VL - 18

SP - 929

EP - 936

JO - Geriatrics and Gerontology International

JF - Geriatrics and Gerontology International

SN - 1447-0594

IS - 6

ER -